Clinical Trials at Sarah Cannon Research Institute

As of July 2026, 60 paid clinical trials are recruiting at Sarah Cannon Research Institute, located at Sarah Cannon Research Institute, 250 25th Ave N, Nashville, TN 37203, phone (615) 329-7274 in Nashville, Tennessee. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Filter results

Filter results

State

City

Facility

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

61 clinical trials at Sarah Cannon Research Institute

·Clear filters·↓ Download CSV

TLN-372 in Advanced KRAS Mutant Solid Tumors

for KRAS Mutant Solid Tumors

Sites in Nashville +5 more locations

Sponsor: Treeline Biosciences, Inc.

Sex: All·Age: 18+

Code: NCT07204340·Phase 1·Recruiting·Listed Oct 2025

Apply to this trial

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

for Hormone Receptor-positive Breast Cancer

Sites in Nashville +5 more locations

Sponsor: Ellipses Pharma

Sex: Female·Age: 18+

Code: NCT05573126·Phase 1, Phase 2·Recruiting·Listed Oct 2022

Apply to this trial

A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

for Unresectable Melanoma

Drug: Lifileucel

Sites in Nashville +2 more locations

Sponsor: Iovance Biotherapeutics, Inc.

Sex: All·Age: 18 - 70

Code: NCT06940739·Phase 1, Phase 2·Recruiting·Listed Apr 2025

Apply to this trial

SNV1521 in Participants With Advanced Solid Tumors

for Advanced Solid Tumor

Sites in Nashville +4 more locations

Sponsor: Synnovation Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06220864·Phase 1·Recruiting·Listed Jan 2024

Apply to this trial

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

for Small Cell Lung Cancer

Drug: Gocatamig

Sites in Nashville +8 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06780137·Phase 1, Phase 2·Recruiting·Listed Jan 2025

Apply to this trial

A Study of JNJ-87890387 for Advanced Solid Tumors

for Neoplasms

Sites in Nashville +1 more location

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06178614·Phase 1·Recruiting·Listed Dec 2023

Apply to this trial

Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma

for Adenoid Cystic Carcinoma

Sites in Nashville +6 more locations

Sponsor: Remix Therapeutics

Sex: All·Age: 18+

Code: NCT06118086·Phase 1, Phase 2·Recruiting·Listed Nov 2023

Apply to this trial

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

for Biliary Tract Cancer

Sites in Nashville +5 more locations

Sponsor: ModeX Therapeutics, An OPKO Health Company

Sex: All·Age: 18+

Code: NCT06239194·Phase 1, Phase 2·Recruiting·Listed Feb 2024

Apply to this trial

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

for Advanced Solid Tumors

Sites in Nashville +7 more locations

Sponsor: Vividion Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05954312·Phase 1·Recruiting·Listed Jul 2023

Apply to this trial

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

for Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors

Drug: Dabrafenib

Sites in Nashville +7 more locations

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 1 - 100

Code: NCT05868629·Recruiting·Listed May 2023

Apply to this trial

SNV4818 in Participants With Advanced Solid Tumors

for Advanced Solid Tumors

Sites in Nashville +4 more locations

Sponsor: Pikavation Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06736704·Phase 1, Phase 2·Recruiting·Listed Dec 2024

Apply to this trial

A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

for Advanced or Metastatic Breast Cancer

1 location in Nashville

Sponsor: Kind Pharmaceuticals LLC

Sex: Female·Age: 18+

Code: NCT05187832·Phase 1·Recruiting·Listed Jan 2022

Apply to this trial

A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma

for Lymphoma

Sites in Nashville +3 more locations

Sponsor: Treeline Biosciences, Inc.

Sex: All·Age: 18+

Code: NCT06733441·Phase 1·Recruiting·Listed Dec 2024

Apply to this trial

A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

for Triple Negative Locally Advanced Non-resectable Breast Cancer

Sites in Nashville +5 more locations

Sponsor: Marengo Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06827613·Phase 1, Phase 2·Recruiting·Listed Feb 2025

Apply to this trial

R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors

for Solid Tumor, Adult

1 location in Nashville

Sponsor: Rise Therapeutics LLC

Sex: All·Age: 18 - 80

Code: NCT06398418·Phase 1·Recruiting·Listed May 2024

Apply to this trial

First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors

for Solid Tumors

Sites in Nashville +2 more locations

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06644755·Phase 1·Recruiting·Listed Oct 2024

Apply to this trial

A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer

for Non-Small Cell Lung Cancer

Sites in Nashville +6 more locations

Sponsor: Avistone Biotechnology Co., Ltd.

Sex: All·Age: 18+

Code: NCT06046495·Phase 1·Recruiting·Listed Sep 2023

Apply to this trial

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

for Neuroendocrine Tumors

Sites in Nashville +3 more locations

Sponsor: Chimeric Therapeutics

Sex: All·Age: 18 - 85

Code: NCT06055439·Phase 1, Phase 2·Recruiting·Listed Sep 2023

Apply to this trial

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

for Metastatic Non-small Cell Lung Cancer

Drug: Osimertinib

Sites in Nashville +15 more locations

Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All·Age: 18+

Code: NCT04410796·Phase 2·Recruiting·Listed Jun 2020

Apply to this trial

Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

for Relapsed Classic Hodgkin Lymphoma

Drug: Nivolumab

Sites in Nashville +4 more locations

Sponsor: City of Hope Medical Center

Sex: All·Age: 18+

Code: NCT04561206·Phase 2·Recruiting·Listed Sep 2020

Apply to this trial